Currently Viewing:
American Diabetes Association (ADA) 2017
Currently Reading
Dr Alan Carter on Biosimilars in the Insulin Market
July 27, 2017
Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities
July 24, 2017
Dr Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research
July 20, 2017
WellDoc Data Offer Promise for Integrating Diabetes Data Into Workflow
July 17, 2017
Dr Alan Carter on the Steps to Managing Rising Insulin Costs
July 17, 2017
Dr Eda Cengiz Discusses the Future of Diabetes Management
July 13, 2017
Nina Brown-Ashford: DPP Will Improve Care and Costs for Prediabetes Patients
July 06, 2017
Dr Alan Carter on Increasing Insulin Costs
July 04, 2017
Dr William Polonsky on Diabetes Patients' Treatment Satisfaction and Insulin Adherence
June 29, 2017
Dr Eda Cengiz on Improvements in Closed-Loop Systems
June 26, 2017
With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million
June 21, 2017
Raymie McFarland Discusses Findings From Glytec's Basal-Bolus Insulin Study
June 21, 2017
Sanofi Presents New Results for Insulin GLP-1 Combo Soliqua
June 13, 2017
Dr Bruce Neal Discusses Canagliflozin's Potential for Heart Failure Prevention
June 13, 2017
Dr Eda Cengiz Explains Artificial Pancreas Systems' Implications for Patients and Clinicians
June 13, 2017
CGM "Debate" Finds Benefits, Barriers to Uptake for Type 2 Diabetes
June 12, 2017
CANVAS Finds Lower Risk of CV Events for Invokana
June 12, 2017
Phase 3 Results Show Lower A1C for Ertugliflozin, Combined With Metformin and With Sitagliptin
June 12, 2017
Heart Failure Needs More Attention in Diabetes Drug Trials, Expert Says
June 11, 2017

Dr Robert Gabbay Highlights 3 Exciting Areas of Developing Diabetes Technology

There are a number of exciting technological advances that could change diabetes care as we know it, such as improved continuous glucose monitors and convenient decision support tools, said Robert Gabbay, MD, PhD, chief medical officer of the Joslin Diabetes Center.


There are a number of exciting technological advances that could change diabetes care as we know it, such as improved continuous glucose monitors and convenient decision support tools, said Robert Gabbay, MD, PhD, chief medical officer of the Joslin Diabetes Center.

Transcript (slightly modified)

What developments in diabetes technology will we see in the next year after the American Diabetes Association Scientific Sessions?

Diabetes technology is about to explode in terms of its impact on diabetes care, and I think there are a few different ways that’s going to happen. One is in the realm of continuous glucose monitors; they’re about to become cheaper, more accurate, and a new one on the market that doesn’t require calibration, ultimately has the potential if it’s inexpensive enough to replace blood glucose monitoring as we know it with a lot more information. That added information could be used to help drive better outcomes for patients with diabetes, so that’s one big exciting area of technology.

The second one I’ll mention is using that continuous glucose data to drive insulin pump changes, and the first step of that is the Medtronic 670G, which will allow titration of insulin through the pump overnight to maintain near-normal glucose levels. It’ll be a self-regulating system, the first time that’s really been available. Initially it’ll be only for a small subset of people, mostly those with type 1 and some with type 2 that are on insulin pumps, but I think that technology will continue to evolve and improve and become more widely available.

The third area that I’ll mention that I think is also very exciting is the decision support tools and the ability to provide real-time information to patients, but also potentially to providers on how to better manage patients, and for patients how to better care for themselves. Being able to capture all the information—glucose levels, activity levels through step counting and other mechanisms, and dietary information—all on somebody’s smartphone to help guide and coach them towards a better lifestyle could be very effective. Similarly, that information transmitted to providers in an intelligible and actionable way could also drive better care.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!